Evonik Industries Ag · XETR:EVK
Evonik Industries — Q2 2026 Earnings Presentation
27 slides from Evonik Industries's earnings presentation, Aug 4, 2026
Slide 1: Evonik Leading Beyond Chemistry – Q2 2026 Results
Evonik Leading Beyond Chemistry Q2 2026 Results August 4, 2026 Christian Kullmann, Chief Executive Officer Michael Rauch, Chief Financial Officer 1
Slide 2: Second quarter ahead of plan – FY guidance raised
Second quarter ahead of plan – FY guidance raised Q2 adj. EBITDA of €630 m (+24% yoy) ahead of expectations mainly due to strong Advanced Technologies Strong Q2 FCF of €49 m (prior year: -€211 m) thanks to better earnings and less bonus payout Efficiency program Evonik Tailor Made extended until 202
Slide 3: Table of contents
Table of contents 1 Highlights and Outlook FY 2026 1 Highlights and Outlook FY 2026 2 Financial performance Q2 2026 2 Financial performance Q2 2026 3 | August 4, 2026 | Evonik Q2 2026 Earnings Conference Call
Slide 4: We continue to execute on our strategy
We continue to execute on our strategy Today In the coming years Weak demand and structural headwinds At least some demand improvement We control our own destiny – We have more potential acting from a position of for improvement strength with our strategy execution ROCE ~11% as soon as possible → Co
Slide 5: Efficiency program Evonik Tailor Made extended until 2029: Additional 3,200 FTEs to be reduced
Efficiency program Evonik Tailor Made extended until 2029: Additional 3,200 FTEs to be reduced 2023-2026 2027-2029 NEW! 2023-2026 Reorganization …2027-2029 Business Procurement “Evonik Tailor “Evonik Tailor Made” extended and expanded optimization optimization Made” + All cost savings and optimizati
Slide 6: Highlights from our three Innovation Growth Areas
Consistently turning innovation into market-ready solutions: Highlights from our three Innovation Growth Areas Advance Precision Biosolutions Enable Circular Economy Accelerate Energy Transition Ecobiol® - Probiotics Specialized DURAION® Membrane in Livestock Production catalysts & adsorbents Streng
Slide 7: Q2 adj. EBITDA of €630 m ahead of expectations mainly due to strong Advanced Technologies
Q2 adj. EBITDA of €630 m ahead of expectations mainly due to strong Advanced Technologies Adj. EBITDA (in € m) / Margin (in %) Drivers of Q2 performance ▪ Solid performance in Custom Solutions (+7% yoy) +24% ▪ Strong Advanced Technologies (+25% yoy) 630 − High volumes in Organics (esp. Crosslin
Slide 8: Strong Q2 FCF of €49 m thanks to better earnings and less bonus payout
Strong Q2 FCF of €49 m thanks to better earnings and less bonus payout Free Cash Flow (in € m) Drivers of H1 performance Q2 H1 ▪ Free cash flow significantly up in H1 (yoy) 232 despite rather stable adj. EBITDA (+3% in H1) 49 − Lower NWC outflow due to strict -211 NWC management − Lower bonu
Slide 9: FY 2026 outlook raised considerably: Adj. EBITDA between €2.0 and 2.2 bn expected
FY 2026 outlook raised considerably: Adj. EBITDA between €2.0 and 2.2 bn expected Adj. EBITDA (in € bn) Outlook by segment “€2.0 - 2.2 bn” Stable on Custom prior-year level “€1.7 - 2.0 bn” Solutions 1.9 (2025: €909 m) Considerably above Advanced prior-year level Technologies (2025: €944 m) Signif
Slide 10: Free Cash Flow outlook confirmed: Targeting ~40% conversion
Free Cash Flow outlook confirmed: Targeting ~40% conversion Free Cash Flow (in € m) / Conversion rate1 (in %) Building blocks for FCF development CCR1 37% ~40% Better operating result 695 Disciplined capex Lower bonus payments (for 2025) NWC with certain headwind from inflation 2025 2026E 1
Slide 11: Table of contents
Table of contents 1 Highlights and Outlook FY 2026 1 Highlights and Outlook FY 2026 2 Financial performance Q2 2026 2 Financial performance Q2 2026 11 | August 4, 2026 | Evonik Q2 2026 Earnings Conference Call
Slide 12: Q2 2026 results overview
Q2 2026 results overview Sales (in € m) Sales (yoy) Adj. EBITDA (in € m) Volume Price +7% +7% 3,893 FX Other 630 (Q2 2025: 3,499) (Q2 2025: 509) -2% -1% Capex1 (in € m) Free Cash Flow (in € m) Adj. EPS (in €) 180 49 0.65 (Q2 2025: 176) (Q2 2025: -211) (Q2 2025: 0.34) 1. Cash outflows for investments
Slide 13: Custom Solutions
Custom Solutions Q2 26 vs. Q2 25 Volume Price FX Other ▪ Good volume and price development; FX headwind +4% +3% -1% -2% subsiding Sales ▪ Sales and order intake on elevated levels esp. in Additives, (in € m) however normalisation towards quarter-end +4% Additives 1,367 1,422 1,334 --- Add
Slide 14: Advanced Technologies
Advanced Technologies Q2 26 vs. Q2 25 Volume Price FX Other Sales Inorganics (adj. EBITDA slightly down yoy) +7% +5% -1% -2% (in € m) ▪ Silica benefits from network optimization Inorganics +9% ▪ Hydrogen Peroxide lower due to license income in previous --- 1,647 year, good volume growth for sem
Slide 15: Infrastructure / Other
Infrastructure / Other Adj. EBITDA (in € m) Thereof: Infrastructure +163% ▪ Oxeno (C4): benefiting from higher margins due to war in the Middle East 100 ▪ Infrastructure: as unusual high level of 47 stability 38 26 Q2 2025 Q1 2026 Q2 2026 7 Thereof: Other -11 -49 -40 -
Slide 16: © evonik
© evonik
Slide 17: Additional indications for FY 2026
Additional indications for FY 2026 Sales Around €15 bn (previously: between €13.5 and 14.5 bn; 2025: €14.1 bn) ROCE Slightly above prior-year level (previously: on prior-year level; 2025: 6.1%) Capex1 ~€750 m (2025: €748 m) EUR/USD sensitivity2 +/-1 USD cent = -/+ ~€5 m adj. EBITDA (FY basis) Adj. D
Slide 18: Adjusted income statement Q2 2026
Adjusted income statement Q2 2026 in € m Q2 2025 Q2 2026 ∆ Sales 3,499 3,893 11% Adj. EBITDA 509 630 24% Adj. tax rate (18%) Depreciation & amortization -259 -260 ▪ Adj. tax rate lower than long-term average Adj. EBIT 250 370 48% (~30%) due to higher earnings share in countries with lower tax rates
Slide 19: Cash flow statement Q2 2026
Cash flow statement Q2 2026 in € m Q2 2025 Q2 2026 CF from operating activities Income before financial result and income taxes (EBIT) 236 163 ▪ Lower (reported) EBIT as starting point Depreciation and amortization 260 376 ▪ Higher impairments, mainly C4 ∆ Net working capital -237 -180 Change in pro
Slide 20: Net financial debt development H1 2026
Net financial debt development H1 2026 3,620 3,311 45 64 34 466 636 404 Dec 31, 2025 F from C ash outflows Dividend payout C Net interest ddition / A Other June 30, 2026 Net financial operating for investments payments reduction in Net financial debt activi
Slide 21: Development of debt and leverage over time
Development of debt and leverage over time Total 3.0x 2.3x 2.4x 2.6x Leverage1 Net financial debt (€3,620 m) 3,310 3,253 3,311 3,620 ▪ Net financial debt up mainly due to Net financial dividend payment debt ▪ Net financial debt leverage stable at (in € m) 1.8x2 Pension provisions (€1,538
Slide 22: Segment overview by quarter
Segment overview by quarter Sales (in € m) Q1/25 Q2/25 Q3/25 Q4/25 FY 2025 Q1/26 Q2/26 Custom Solutions 1,427 1,367 1,340 1,359 5,492 1,334 1,422 Advanced Technologies 1,601 1,511 1,445 1,415 5,973 1,450 1,647 Infrastructure / Other1 749 621 606 629 2,604 643 824 Evonik Group 3,777 3,499 3,391 3,403
Slide 23: Update on business optimization programs
Update on business optimization programs Secure competitive position and deliver savings High Performance Coating & Crosslinkers Amino Acids Silica/Silanes Health Care Polymers Adhesive Resins (i-Chain) Start date Q2 2023 Q1 2024 Q4 2023 Q1 2024 Q1 2024 Q1 2024 Full potential End of 2026 End of 2027
Slide 24: Upcoming IR events
Upcoming IR events Conferences & roadshows Upcoming reporting dates & events August 5, 2026 Roadshow Frankfurt (Oddo) November 3, 2026 Q3 2026 Reporting September 2, 2026 Roadshow London (Citi) March 4, 2027 Q4/FY 2026 Reporting September 2, 2026 Roadshow Amsterdam May 4, 2027 Q1 2027 Reporting Sept
Slide 25: Evonik Investor Relations Team
Evonik Investor Relations Team Christoph Finke Cédric Schupp Senior Vice President Investor Relations Director Investor Relations & ESG +49 174 9931647 +49 173 2552453 christoph.finke@evonik.com cedric.schupp@evonik.com Katharina Gayk Johanna Göbel Specialist Investor Relations Senior Manager Invest
Slide 26: Disclaimer
Disclaimer In so far as forecasts or expectations are expressed in this presentation or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the oper
Slide 27: © evonik
© evonik